AltheaDx: Bringing Theranostics into Clinical Use

May 21, 2009	AltheaDx Receives CLIA Certification
Expanding their service offering with clinical laboratory testing.
May 19, 2009	Eric Topol Appointed to the AltheaDx Scientific Advisory Board
Key appointment of a leader in translational medicine - Eric J. Topol, M.D.
May 08, 2009	Greg Tsongalis Appointed to the AltheaDx Scientific Advisory Board
Key appointment of a well respected clinician Gregory J. Tsongalis, Ph.D., HCLD, FACB.
April 27, 2009	AltheaDx Forms Scientific Advisory Board
Key appointments include Doctors and Researchers from Industry and Academia.
April 16, 2009	AltheaDx Expands Genotyping Menu for Drug Metabolism
New microarray offering expands existing capabilities with Affymetrix' Drug Metabolizing Enzymes and Transporters (DMET Plus) for comprehensive genetic studies of pharmacokinetics.
March 24, 2009	Clinical Researchers Get New Tool to Ensure Accuracy of Genetic Testing
AltheaDx launches world’s first assay to test quality of RNA isolated from FFPE specimens.s
November 04, 2008	AltheaDx to offer the DxS K-RAS test for clinical studies
DxS K-RAS test will assist US oncologists in studying patient response to cancer therapies in clinical trials.
April 15, 2008	AltheaDx Appoints Vice President of Business Development, Sales and Marketing
AltheaDx, Inc. announced today that Cyrus Mirsaidi has been appointed Vice President of Business Development, Sales and Marketing, reporting directly to the CEO.
April 15, 2008	AltheaDx Named Affymetrix Authorized Service Provider
AltheaDx, a leading provider of contract testing services to the pharmaceutical and biotechnology industry, today announced a supply and service provider agreement with Affymetrix Inc. (Nasdaq:AFFX). The agreement enables AltheaDx to offer complete biomarker discovery and development services based on the Affymetrix GeneChip microarray platform. AltheaDx, a recent spin-out of Althea Technologies, is making the services available to customers worldwide.
April 14, 2008	Poniard Pharmaceuticals and AltheaDx Sign Agreement - Poniard to investigate molecular signatures for platinum resistance
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has selected AltheaDx, Inc.'s Express Pathway program to identify molecular signatures which may be correlated to platinum resistance.
March 04, 2008	AltheaDx Board of Directors Appoints Industry Veteran CEO
Althea Diagnostics Incorporated announced today that David Macdonald has been appointed the Chief Executive Officer of the firm.
February 26, 2008	Althea Technologies Announces the Spin-out of an Independent Company, AltheaDx
Althea Technologies, Inc., a leading provider of innovative technologies and pharmaceutical services, announced today that it has spun-out an independent company to commercialize its breakthrough genetic testing technology through a variety of laboratory services and gene expression products for use in monitoring and managing cancer treatment.
October 02, 2007	Althea Technologies Expands Collaboration with BiPar Sciences
Althea Technologies, Inc., today announced the expansion of a collaboration with BiPar Sciences, Inc. to provide pharmacogenomic support for BiPar's drug development programs in oncology.
February 20, 2007	Althea Technologies Announces the Development of a Diagnostic Capable of Differentiating Multiple Forms of Childhood Cancer
Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today the development of a molecular diagnostic capable of clearly differentiating various types of childhood cancers resulting from collaborative efforts between Althea and the U.S. National Cancer Institute (NCI).
February 01, 2007	Althea Technologies and Blueshift Biotechnologies Combine Technologies for High Throughput, Gene Expression Screening
Althea Technologies, Inc. and Blueshift Biotechnologies announced today that Althea has received a SBIR award from the National Human Genome Research Institute to explore the potential for practical high throughput and low cost gene expression analysis.
November 08, 2005	Althea Introduces Time Saving Assay For Predicting Carcinogenicity Using Pcr- Based Gene Expression Profiling
Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and clinical evaluation, and Natural Selection, Inc. (NSI), a leader in the application of sophisticated computational intelligence algorithms to problems in bioinformatics, announced the introduction of an novel lead compound toxicity classification assay employing multiplex gene expression screening paired with neural network analysis.
September 30, 2005	Althea Launches Glp Clinical Gene Expression Services Using Beckman Coulter’s Gexp Quantitative Multiplexed PCR System
Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and clinical evaluation, announced the introduction of Good Laboratory Practices (GLP) compliant testing services for routine gene expression analysis of clinical samples.
May 17, 2005	Althea Presents Application Of Gene Expression Technology For Cancer Diagnostics At The American Society Of Clinical Oncology Meeting
Althea Technologies, Inc., a leading provider of innovative technologies for pharmaceutical and clinical services, announced that application of its multiplexed PCR technology for quantitative gene expression in cancer diagnosis will be presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 13 – 17, 2005, in Orlando, Florida.
April 19, 2005	Althea Awarded NCI Grant To Apply Innovative Technology In Compound Library Expression Screening
Althea Technologies, Inc., a leading provider of innovative technologies for pharmaceutical services and manufacturing, announced today that it has received an R01 grant from the National Cancer Institute (NCI), of the National Institutes of Health.
December 1, 2004	Natural Selection and Althea Technologies in Strategic Alliance to Provide Gene Expression Biomarker Discovery
Althea Technologies, Inc., a leading provider of innovative technologies and services in gene expression analysis, and Natural Selection, Inc. (NSI), a leader in the application of sophisticated computational intelligence algorithms to problems in bioinformatics, announced today that the companies have signed a collaborative agreement to provide a new range of services.
October 19, 2004	Althea Awarded NCI Grant To Apply Innovative Technology in Diagnosis of Childhood Cancers
Althea Technologies, Inc., a leading provider of innovative technologies for pharmaceutical services and manufacturing, announced today that it has received a Phase I SBIR grant from the National Cancer Institute (NCI), of the National Institutes of Health.
June 23, 2004	Althea Awarded Innovative Toxicology Grant From NIH
Althea Technologies, Inc., a leading provider of innovative technologies for pharmaceutical services and manufacturing, announced today that it has received a Phase I SBIR grant from the Innovative Toxicology Models Program of the National Institutes of Health, by way of the National Institute on Deafness and Other Communication Disorders (NIDCD).
June 03, 2004	Beckman Coulter Signs Agreement With Althea Technologies For Gene Expression Technology
Beckman Coulter, Inc. (NYSE:BEC) today announced it has entered into an exclusive licensing agreement with Althea Technologies, Inc. for Althea’s proprietary eXpress Profiling™ technology. Beckman Coulter plans to integrate eXpress Profiling into its GenomeLab suite of genetic analysis solutions to speed drug discovery.
September 15, 2003	Althea Announces Issuance Of U.S. Patent For High Throughput Gene Expression Analysis
Althea Technologies, Inc., a leading provider of gene-based manufacturing and testing services to accelerate drug development, announced today that it has been granted U.S. Patent number 6,618,679 covering its eXpress Profiling™ technology.
May 05, 2003	Althea Awarded Technology Grant
Althea Technologies, Inc., a leading provider of gene-based manufacturing and testing services to accelerate drug development, announced today that it has received a Phase I Small Business Innovation Research grant from the National Institutes of Health, by way of the National Cancer Institute (NCI), to develop a new production-oriented, high-throughput approach to gene expression analysis for cancer.
March 12, 2003	Althea Presents Multiplex Pcr Data Related To Toxicogenomics
Althea Technologies, Inc., a leader in gene expression analysis, announced today that it presented data illustrating that its quantitative, multiplex PCR technology, eXpress Profiling™, can successfully monitor the impact of compounds on the expression of selected genes for early toxicological screening in a high-throughput format.
February 11, 2003	Althea’s Express Profiling Technology Used In High- Throughput Multiplexed Gene Expression Study
Althea Technologies, Inc., a leader in high- throughput, gene expression analysis, announced today that the results of a pioneering study using multiplexed gene expression in compound library screening were published in the December 2002 edition of the journal Molecular Cancer Therapeutics.
October 19, 2000	Althea Technologies, Inc. Offers Full Scope Custom Integration Study Assays For DNA Vaccines
Althea Technologies, Inc., www.altheatech.com, announced today that they now offer a full scope custom Integration Study to test for genomic integration of plasmid DNA vaccine products in injected animal muscle tissues. Each study includes a complex protocol of procedures designed to separate high molecular weight DNA from low molecular weight plasmid-derived DNA with a custom designed very sensitive and specific quantitative real time PCR amplification assay.

Events